Business

Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma

Financial Post · September 14, 2026 at 1:00 a.m.

GHENT, Belgium & TOKYO -- H.U.

Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE ® G immunoassay platform in Brazil.

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma

More from Financial Post

Orca Energy Group Provides Update on Songo Songo Licence, Operations, and the Proposed Transaction

Canada’s new Defence Investment Agency could be a ‘driver’ for these TSX stocks, says analyst

News of the day: Small businesses, job losses, heat pumps, interest rates, marital assets and more

NexGold Reminds Warrant Holders of Upcoming Expiry

More in Business

Orca Energy Group Provides Update on Songo Songo Licence, Operations, and the Proposed Transaction

Canada’s new Defence Investment Agency could be a ‘driver’ for these TSX stocks, says analyst

News of the day: Small businesses, job losses, heat pumps, interest rates, marital assets and more

NexGold Reminds Warrant Holders of Upcoming Expiry

Vancouver’s court-ordered property listings are nearing a 20-year high — and they’re not selling

Gran Tierra Energy Inc. Stockholders Approve Sale of Colombian and Ecuadorian Businesses